Clinical trial
A Phase 2 Open-Label Extension Study to Evaluate the Safety and Pharmacodynamics of Belcesiran in Patients With PiZZ Alpha-1 Antitrypsin Deficiency Associated Liver Disease
NCT05146882 is registered in ClinicalTrials.gov with Dicerna Pharmaceuticals, Inc., a Novo Nordisk company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Open-Label Extension Study to Evaluate the Safety and Pharmacodynamics of Belcesiran in Patients With PiZZ Alpha-1 Antitrypsin Deficiency Associated Liver Disease
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- December 31, 2021
- Completion date
- May 23, 2022
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.